Saturday, January 19, 2013

• Big Pharma Diabetes Face-Offat Motley Fool (Sat, Jan 19)
• The Amazing P53 Raceat Seeking Alpha (Sat, Jan 19)

Friday, January 18, 2013

• Supreme Court Decision Is Bullish For Stem Cell Companiesat Seeking Alpha (Fri, Jan 18)
• Litespeed Management’s Best Stock Picksat Motley Fool (Fri, Jan 18)
• XenoPort: Biogen's Little Brother And Moreat Seeking Alpha (Fri, Jan 18)
• Pharma's Reputation Continues to Suffer -- What Can Be Done To Fix It?at Forbes (Fri, Jan 18)
• Deja Vu: A 10% Jump for That?at Motley Fool (Fri, Jan 18)

Thursday, January 17, 2013

• Why GlaxoSmithKline Is Poised to Popat Motley Fool (Thu, Jan 17)
• AbbVie, Abbott Spinoff, Starts Life Near Top of Pharma Industry’s Dividend-Yield HeapYCharts (Thu, Jan 17)
• FTC: Pay-to-Delay Pharma Deals Cover $8.3 Billion in RevenueYCharts (Thu, Jan 17)
• 3 Super Dividend Healthcare Stocksat Motley Fool (Thu, Jan 17)
• Theravance to Offer NotesZacks (Thu, Jan 17)
• Medicago nabs $15M loan from partnerat bizjournals.com (Thu, Jan 17)

Wednesday, January 16, 2013

• CAPScall of the Week: Amicus Therapeuticsat Motley Fool (Wed, Jan 16)
• Prepare To Profit From Global Takeoversat Seeking Alpha (Wed, Jan 16)
• Pfizer: Buy, Sell Or Hold?at Seeking Alpha (Wed, Jan 16)
• Can GlaxoSmithKline Outperform Pfizer?at Motley Fool (Wed, Jan 16)
• Perrigo Launches Generic Luxiq FoamZacks (Wed, Jan 16)

Tuesday, January 15, 2013

• Arena: A Share Price Modelat Seeking Alpha (Tue, Jan 15)
• The Best of Big Pharma for 2013at Motley Fool (Tue, Jan 15)
• Glaxo Seeks Albiglutide ApprovalZacks (Tue, Jan 15)

Monday, January 14, 2013

• XOMA's Gevokizumab Study UpdateZacks (Mon, Jan 14)
• JPMorgan Healthcare Conference Highlights: Exelixisat Motley Fool (Mon, Jan 14)
• GlaxoSmithKline Aims to Compete in Packed Field of Diabetes Drugsat Minyanville (Mon, Jan 14)
• There's Value in Studying Big Pharma Pipelinesat Forbes (Mon, Jan 14)

Add GSK News to My Yahoo!